港股異動丨中國鐵塔(00788.HK)連續反彈 5日累計漲近12% 近期獲多家投行唱好
格隆匯11月6日丨中國鐵塔(00788.HK)近日股價開始反彈,5日累漲近12%,此前曾創近2年新低價。現報1.36港元,漲6.25%,暫成交10.4億港元,總市值2393.7億港元。近日公司受到多家投行的關注,瑞信指出,中國鐵塔已超賣,維持“跑贏大市”評級;大摩料中國鐵計劃增加派息比率,給予目標價1.8港元。但野村降中國鐵塔目標價至1.63港元,仍舊維持“買入”評級。招商證券(香港)表示,公司在未來將開發創新的建造和定價安排,這將減輕資本支出負擔,同時影響收入增長,預計2021-22年中國鐵塔收入將增長7%-8%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.